Zymeworks Announces $200 Million Share Repurchase Authorization
Key Highlights
- ➤Zymeworks (ZYME) authorizes up to $200.0 million in share repurchases through 2028
- ➤Zymeworks expects approximately $140.0 million in repurchases through 2028
- ➤Program funding includes $55 million Roche fees and potential $100 million TRELEGY milestone
- ➤Zymeworks completed its initial 2026 program authorized for up to $125.0 million
- ➤Zymeworks plans 2027 capital allocation across R&D, selective M&A and repurchases
Expert Statements
Kristin Stafford, Chief Financial Officer of Zymeworks
“As we look ahead, our focus remains on allocating capital thoughtfully to support long-term growth and shareholder value”
Kristin Stafford, Chief Financial Officer of Zymeworks
“Our priorities include disciplined pipeline development, selective M&A and opportunistic share repurchases, with $140.0 million in repurchases expected through 2028. Maintaining flexibility around the pace of repurchases allows us to respond to market conditions and cash flow while prioritizing opportunities to create lasting value for shareholders.”
* Zymeworks intends to commence the Share Repurchase Program with $140.0 million in share repurchases expected through 2028, with flexibility to adjust the pace of repurchases based on market opportunities, cash flow, and expected contribution to Total Shareholder Return (TSR) * Zymeworks intends to balance capital allocation for 2027 thoughtfully across disciplined R&D pipeline development, selective M&A transactions and opportunistic share repurchases to grow underlying enterprise value while returning capital to shareholders through reducing share count over time VANCOUVER, British Columbia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its Board of Directors has authorized a second 2026 share repurchase program under which the Company may repurchase up to $200.0 million of its outstanding common stock, par value $0.00001 per share.
Get started
Create a free account to read the full story.
